• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by OptimizeRx Corporation

    4/30/25 11:22:15 AM ET
    $OPRX
    Business Services
    Consumer Discretionary
    Get the next $OPRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    OptimizeRx Corp

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    68401U204

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68401U204


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    16,989.00
    7Sole Dispositive Power

    897,962.00
    8Shared Dispositive Power

    23,886.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    921,848.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.98 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    OptimizeRx Corp
    (b)Address of issuer's principal executive offices:

    260 Charles Street, Suite 302, Waltham, MA, 02453
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    68401U204
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    921848
    (b)Percent of class:

    4.98  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    16989

     (iii) Sole power to dispose or to direct the disposition of:

    897962

     (iv) Shared power to dispose or to direct the disposition of:

    23886

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:04/30/2025
    Get the next $OPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPRX

    DatePrice TargetRatingAnalyst
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    12/20/2024$5.50Equal-Weight
    Stephens
    7/25/2024$18.50Buy
    B. Riley Securities
    4/4/2024$15.00Mkt Outperform
    JMP Securities
    1/3/2024$15.00Equal Weight
    Barclays
    2/2/2023$30.00Buy
    B. Riley Securities
    11/1/2022$19.00Buy
    Stifel
    7/15/2022$38.00Outperform
    SVB Leerink
    More analyst ratings

    $OPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report

      WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2025. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibilities as a corporate citizen. "Our stakeholders continue to expect us to transparently disclose our commitment to environmental, social, and governance responsibilities," stated Marion

      5/1/25 4:05:00 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET

      WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Monday, May 12, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Toll Free

      4/23/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment

      WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx's ongoing process to refresh and expand its board of directors (the "Board"), it intends to appoint a new independent director to its Board of Directors during the second half of this year.  With the appointment of a new independent director in 2025, OptimizeRx will have refreshed its Board, which is currently comprised of five directors, with three new directors since 2020, including Catherine Klema w

      4/18/25 4:15:53 PM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment

      WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx's ongoing process to refresh and expand its board of directors (the "Board"), it intends to appoint a new independent director to its Board of Directors during the second half of this year.  With the appointment of a new independent director in 2025, OptimizeRx will have refreshed its Board, which is currently comprised of five directors, with three new directors since 2020, including Catherine Klema w

      4/18/25 4:15:53 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer

      WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company's new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a

      3/10/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO

      WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition. "The time is right to pass the reins on to an incredible team, ready to carry the legacy forwa

      12/23/24 8:45:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      3/19/25 7:40:24 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Chief Commercial Officer Silvestro Stephen L converted options into 1,928 shares and covered exercise/tax liability with 572 shares, increasing direct ownership by 1% to 121,314 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      3/4/25 9:18:21 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Chief Legal Officer & CHRO Odence-Ford Marion converted options into 771 shares and covered exercise/tax liability with 268 shares, increasing direct ownership by 0.72% to 70,276 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      3/4/25 9:16:52 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • OptimizeRx downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

      1/8/25 8:17:01 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Stephens initiated coverage on OptimizeRx with a new price target

      Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

      12/20/24 7:46:38 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • B. Riley Securities resumed coverage on OptimizeRx with a new price target

      B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50

      7/25/24 8:24:56 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

      SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

      12/6/24 4:26:03 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by OptimizeRx Corporation

      SC 13G - OptimizeRx Corp (0001448431) (Subject)

      11/14/24 3:18:35 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

      SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

      11/14/24 11:25:34 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Financials

    Live finance-specific insights

    See more
    • OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET

      WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Monday, May 12, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Toll Free

      4/23/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results

      Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.  For the Year EndedDecember 31,Key Performance Indicators (KPIs)* 2024   2023  (in thousands, except percentages)Average revenue per top 20 pharma

      3/12/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET

      WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, March 12, 2025, at 8:30 a.m. Eastern Time to discuss full year fiscal 2024 financial results and the fourth quarter period ended December 31, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Wednesday, March 12, 2025Time:8:30 a.m. Easte

      2/27/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by OptimizeRx Corporation

      SCHEDULE 13G/A - OptimizeRx Corp (0001448431) (Subject)

      4/30/25 11:22:15 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • SEC Form DEF 14A filed by OptimizeRx Corporation

      DEF 14A - OptimizeRx Corp (0001448431) (Filer)

      4/30/25 8:30:20 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - OptimizeRx Corp (0001448431) (Filer)

      4/18/25 4:30:08 PM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      3/19/25 7:40:24 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      12/16/24 2:28:39 PM ET
      $OPRX
      Business Services
      Consumer Discretionary